Effects of ondansetron administration on opioid withdrawal syndrome observed in rats

European Journal of Pharmacology

Volumn 340, Issue 2-3, 1997, Pages 111-119

  Pinelli, Arnaldo ^a   Trivulzio, Silvio ^a   Tomasoni, Livio ^a  

^a Chemotherapy and Medical Toxicology ^*  (Italy)

Author keywords

Ondansetron; Opioid withdrawal syndrome; Rat; Withdrawal

Indexed keywords

MORPHINE; NALOXONE; ONDANSETRON;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEFECATION; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICTURITION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE; SALIVATION; SYMPTOM; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; DEFECATION; MALE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; ONDANSETRON; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; SALIVATION; SEROTONIN ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME; URINATION;

EID: 0031565151     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01349-6     Document Type: Article

References (43)

1. Aceto M.D., Bowman E.R. Suppression of opiate withdrawal and cocaine hyperarousal syndromes by buspirone. Possible pharmacotherapeutic applications. Arzneim. Forsch. 43:1993;942-945.
2. Acquas E., Carboni E., Leone P., Di Chiara G. 5HT3 receptor antagonists block morphine- and nicotine- but not amphetamine-induced place-preference conditioning. Pharmacol. Res. Commun. 20:1988;1113-1114.
3. Armitage, P., 1991. Statistica Medica, X ed. Feltrinelli, Milan.
4. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome and self-administrative behaviour. Pharmacol. Rev. 46:1994;293-324.
5. Beubler E., Bukhave K., Rask-Madsen J. Colonic secretion mediated by prostaglandin E2 and 5-hydroxytryptamine may contribute to diarrhea due to morphine withdrawal in the rat. Gastroenterology. 87:1984;1042-1048.
6. Borg P.J., Taylor D.A. Voluntary oral morphine self-administration in rats: Effect of haloperidol or ondansetron. Pharmacol. Biochem. Behav. 47:1994;633-646.
7. Bradley P.B., Engel G., Feniuk W., Fozard J.R., Humphrey P.P., Middlemiss D.N., Mylecharane E.J., Richardson B.P., Saxena P.R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 25:1986;563-576.
8. Buccafusco J.J., Marshall D.C., Turner R.M. A comparison of the inhibitory effects of clonidine and guanfacine on the behavioural and autonomic components of morphine withdrawal in rats. Life Sci. 35:1984;1401-1408.
9. Carruba M.O., Nistico G., Mantegazza P. Evidence for a receptor supersensitivity following impairment of central serotoninergic activity in the rabbit. N.S. Arch. Pharmacol. 309:1979;125-129.
10. Cervo L., Rochat C., Romandini S., Samanin R. Evidence of a preferential role of brain serotonin in the mechanisms leading to naloxone-precipitated compulsive jumping in morphine-dependent rats. Psychopharmacology. 74:1981;271-274.
11. Corsi M., Pietra C., Toson G., Trist D., Tuccitto G., Artibani W. Pharmacological analysis of 5-hydroxytryptamine effects on electrically stimulated human isolated urinary bladder. Br. J. Pharmacol. 104:1991;719-725.
12. Costall B., Domeney A.M., Naylor R.J., Tyers M.B. Effects of 5HT3 receptor antagonist GR38032 F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br. J. Pharmacol. 92:1987;881-894.
13. Costall B., Naylor R.J. Astra award lecture. The psychopharmacology of 5HT3 receptors (review). Pharmacol. Toxicol. 71:1992;401-415.
14. Cowan, A., 1993. Effects of opioids on the spontaneous behaviour of animals. In: Herz, A., Akil, H., Simon, E.J. (Eds.), Opioids II. Springer-Verlag, Berlin, pp. 393-428.
15. El-Kadi A.O., Sharif S.I. The role of 5-HT in the expression of morphine withdrawal in mice. Life Sci. 57:1995;511-516.
16. 3 receptor antagonists in the mouse. Neuropharmacology. 28:1989;423-427.
17. 2 receptors of morphine tolerant-dependent rats. Neuropharmacology. 27:1988;1231-1237.
18. 2 receptors of morphine-tolerant-dependent and abstinent rats. Eur. J. Pharmacol. 167:1989;185-192.
19. 1A receptors in morphine abstinent rats. Eur. J. Pharmacol. 182:1990;253-259.
20. Harris L.S., Dewey W.L., Howes J.F., Kennedy J.S., Pars H. Narcotic-antagonist analgesics, interactions with cholinergic systems. J. Pharmacol. Exp. Ther. 169:1969;17-22.
21. 3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. Psychopharmacology. 105:1991;322-328.
22. 3 receptor antagonists, MDL 72222 and ondansetron on morphine place conditioning. Psychopharmacology. 106:1992;315-320.
23. Hui S.C., Sevilla E.L., Ogle C.W. 5HT3 antagonists reduce morphine self-administration in rats. Br. J. Pharmacol. 110:1993;1341-1346.
24. Hui S.C., Sevilla E.L., Ogle C.W. Prevention by 5HT3 receptor antagonist, ondansetron, of morphine-dependence and tolerance in the rat. Br. J. Pharmacol. 118:1996;1044-1050.
25. Kromer, W., 1993. Gastrointestinal effects of opioids, In: Herz, A., Akil, H., Simon, E.J. (Eds.), Opioids II. Springer-Verlag, Berlin, pp. 163-190.
26. Kruszewska A., Langwinski R. The role of central serotoninergic neurotransmission in the morphine abstinence syndrome in rats. Drug Alcohol Depen. 12:1983;273-278.
27. Lal H. Narcotic dependence, narcotic action and dopamine receptors. Life Sci. 17:1975;483-495.
28. Lamers C.B. Closing remarks: Ondansetron effects on gastrointestinal motility. Scand. J. Gastroentero. 188 (Suppl.):1991;124-126.
29. Legarda J.J., Gossop M. A 24-h inpatient detoxification treatment for heroin addicts: A preliminary investigation. Drug Alcohol Depen. 35:1994;91-93.
30. Martin, W.R., Jasinski, D.R., 1977. Assessment of the abuse potential of narcotic analgesics in animals. In: Martin, W.R. (Ed.), Handbook of Experimental Pharmacology, vol. 45/1. Springer-Verlag, Berlin, ch. 2, pp. 159-196.
31. Mazzola-Pomietto P., Aulakh C.S., Murphy D.L. Temperature, food intake and locomotor activity effects of 5-HT3 receptor agonist and two 5-HT3 receptor antagonist in rats. Psycopharmacology. 121:1995;488-493.
32. 3 receptor antagonist, ondansetron, on brain stimulation reward and its interaction with direct and indirect stimulants of central dopaminergic transmission. J. Neural. Transm.-Gen. 9:1993;1-11.
33. Neal B.S., Sparber S.B. Mianserin attenuates naloxone-precipitated withdrawal signs in rats acutely or chronically dependent upon morphine. J. Pharmacol. Exp. Ther. 236:1986;157-165.
34. Neal B.S., Sparber S.B. Ketanserin and pirenperone attenuate acute morphine withdrawal in rats. Eur. J. Pharmacol. 132:1986;299-304.
35. Pei Q., Zetterstrom T., Leslie R.A., Grahame-Smith D.G. 5TH3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur. J. Pharmacol. 230:1993;63-68.
36. Redmond D.E. Jr., Krystal J.H. Multiple mechanisms of withdrawal from opioid drugs. Annu. Rev. Neurosci. 7:1984;443-478.
37. Samanin R., Cervo L., Rochat C., Poggesi E., Mennini T. Reduction in the number of serotonin receptors in the brainstem of morphine dependent rats: relation to blockade of naloxone precipitated jumping by serotonin agonists. Life Sci. 27:1980;1141-1146.
38. Samanin R., Cervo L., Rochat C. Changes of physical morphine dependence in rats chronically treated with drugs acting on brain 5-hydroxytryptamine. J. Pharm. Pharmacol. 32:1980;150.
39. Sell L.A., Cowen P.J., Robson P.J. Ondansetron and opiate craving. A novel pharmacological approach to addiction. Br. J. Psychiatry. 166:1995;511.
40. Sufka K.J., Schomburg F.M., Giordano J. Receptor mediation of 5-HT induced inflammation and nociception in rats. Pharmacol. Biochem. Behav. 41:1992;53-56.
41. 3 receptor antagonist slows colonic transit in healthy man. Digest. Dis. Sci. 35:1990;477-480.
42. Van der Laan J.W., Hillen F.C. The potentiation of morphine-withdrawal jumping by clonidine is antagonized by m-chlorophenylpiperazine and not by haloperidol. Arch. Int. Pharmacod. T. 283:1986;45-55.
43. Zifa E., Fillon G. 5-Hydroxytryptamine receptors. Pharmacol. Rev. 44:1992;401-458.